A national cohort study found that the incidence of triple-negative breast cancer (TNBC) is highest among Black women living in the most socioeconomically disadvantaged neighborhoods, and the ...

Immunotherapy has emerged as a key treatment approach for several solid tumors. However, its role in early-stage breast cancer continues to evolve. The immune microenvironment of breast cancer is ...

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients. DB-1305/BNT325, a TROP2-targeted antibody ...

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment. “We're hoping that this is a broader ...

SAGA Diagnostics®, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, joined ...

Researchers at the University of California, Los Angeles (UCLA), have developed a new type of allogeneic immune cell therapy that demonstrated potent antitumor activity against triple-negative breast ...

Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...

SAN ANTONIO -- More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a ...

Tecentriq addition to chemotherapy increased chemotherapy-induced ovarian failure rates in early triple-negative breast cancer patients, though no statistical differences were found between treatment ...